Skip to main content
SpringerLink
Log in

Do T3 Rectal Cancers Always Need Radiochemotherapy?

  • Chapter
  • First Online:
Early Gastrointestinal Cancers II: Rectal Cancer

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 203))

Abstract

The limitation of the traditional method of stratifying patients with rectal cancer for prognosis using magnetic resonance imaging (MRI) and computerised tomography (CT)—TNM staging—is that cT3 tumors comprise the vast majority of rectal cancers. There is a wide variability in outcomes for cT3. Despite this observation, many still advocate routine short course preoperative radiotherapy (SCPRT) or chemoradiation (CRT) for all patients staged as cT3N0 regardless of tumour location, proximity to other structures or extent, despite the fact that advances in imaging with MRI now offer the ability to predict potential outcomes in terms of the risk of local and metastatic recurrence for the individual. Preoperative CRT is designed to reduce local recurrence. The majority of local recurrences historically reflected inadequate quality of the mesorectal resection. Currently, optimal quality-controlled surgery in terms of total mesorectal excision (TME) in the trial setting can be associated with much lower local recurrence rates of less than 10 % whether patients receive radiotherapy or not. Because of the high risk of metastatic disease in selected patients, integrating more active chemotherapy is now attractive. Chemoradiotherapy (CRT) achieves shrinkage and sometimes eradication of tumour—i.e. a pathological complete response (pCR), and reduces local recurrence, but has no impact on overall survival. CRT also increases surgical morbidity and impacts on anorectal, urinary and sexual function with an increased risk of second malignancies. Hence, the predominant aims of CRT have been to shrink/downstage a tumour to allow an R0 resection to be performed, or to increase the chances of performing sphincter-sparing surgery. However, it remains unclear why shrinkage/downstaging is meaningful to a patient unless the tumour is initially borderline resectable or unresectable (i.e. the CRM is threatened) or the aim is to perform a lesser operation (i.e. sphincter-sparing or local excision) or for organ-sparing, i.e. to avoid surgery altogether. If it is important to shrink the cancer—ie there is a predicted threat to the CRM, then CRT is currently the treatment of choice. If the cancer is resectable and the aim is simply to lower the risk of local recurrence and preoperative CRT does not impact on survival, can CRT be omitted in selected cases? The answer is yes—with the proviso that we are using good quality MRI and the surgeon is performing good quality TME surgery within the mesorectal plane.

Conflict of interest statements:

Rob Glynne-Jones has received honoraria for lectures and advisory boards, and has been supported in attending international meetings in the last 5 years by Eli Lilley, Merck, Pfizer, Sanofi-Aventis and Roche. He has also in the past received unrestricted grants for research from Merck-Serono, Sanofi-Aventis and Roche. He is principal investigator of a randomised phase II neoadjuvant chemotherapy study in the UK called ‘BACCHUS’

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 54.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Akasu T, Moriya Y, Ohashi Y, Yoshida S, Shirao K, Kodaira S (2006) National surgical adjuvant study of colorectal cancer. adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. Jpn J Clin Oncol 36(4):237–244

    Article  PubMed  Google Scholar 

  • André T, Boni C, Navarro M et al (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27(19):3109–3116

    Article  PubMed  Google Scholar 

  • Aschele C, Cionini L, Lonardi S et al (2011) Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 29(20):2773–2780

    Article  CAS  PubMed  Google Scholar 

  • Birgisson H, Pahlman L, Gunnarsson U, Glimelius B (2005) Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 23:6126–6131

    Article  PubMed  Google Scholar 

  • Birgisson H, Pahlman L, Glimelius B (2006) Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish rectal cancer trial. J Clin Oncol 23:8697–8705

    Article  Google Scholar 

  • Bondeven P, Hagemann-Madsen RH, Bondeven P, Hagemann-Madsen RH, Laurberg S, Pedersen BG (2013) Extent and completeness of mesorectal excision evaluated by postoperative magnetic resonance imaging. Br J Surg 100(10):1357–1367

    Article  CAS  PubMed  Google Scholar 

  • Bosset JF, Collette L, Calais G et al (2006) Chemoradiotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355:1114–1123

    Article  CAS  PubMed  Google Scholar 

  • Bosset JF, Calais G, Mineur L,et al (2014) EORTC radiation oncology group. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 15(2):184–190

    Google Scholar 

  • Braendengen M, Tveit KM, Berglund A et al (2008) Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. J Clin Oncol 26(22):3687–3694

    Article  CAS  PubMed  Google Scholar 

  • Bujko K, Nowacki MP, Nasierowska-Guttmejer A et al (2006) Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 93(10):1215–1223

    Article  CAS  PubMed  Google Scholar 

  • Cecil DT, Sexton R, Moran BJ, Heald RJ (2004) Total Mesorectal excision results in low local recurrence rates in lymph node-positive rectal cancer. Dis Colon Rectum 47:1145–1150

    Article  PubMed  Google Scholar 

  • Cercek A, Weiser MR, Goodman KA, et al (2010) Complete pathological response in the primary of rectal or colon cancer treated with FOLFOX without radiation. J Clin Oncol 28(15S suppl May 20 Supplement):297s (abstract 3649)

    Google Scholar 

  • Chua YJ, Barbachano Y, Cunningham D et al (2010) Neoadjuvant capecitabine and oxaliplatin before chemoradiation and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial. Lancet Oncol 11(3):241–248

    Article  CAS  PubMed  Google Scholar 

  • Dirschmid K, Lang A, Mathis G et al (1996) Incidence of extramural venous invasion in colorectal carcinoma: findings with a new technique. Hum Pathol 27(11):1227–1230

    Article  CAS  PubMed  Google Scholar 

  • Douglas HO Jr, Moertel CG, Mayer RJ, Thomas PR, Lindblad AS, Mittleman A et al (1986) Survival after postoperative combination treatment of rectal cancer. N Engl J Med 315:1294–1295

    Article  Google Scholar 

  • Fernandez-Martos C, Pericay C, Salud A (2011) Three-year outcomes of GCR-3: a phase II randomized trial comparing conventional preoperative chemoradiation (CRT) followed by surgery and postoperative adjuvant chemotherapy (CT) with induction CT followed by CRT and surgery in locally advanced rectal cancer. J Clin Oncol 29(suppl; abstr 3552)

    Google Scholar 

  • Fernandez-Martos C, Estevan R, Salud A et al (2012) Neoadjuvant capecitabine, oxaliplatin and bevacizumab (CAPOX-B) in intermedicate-risk rectal cancer (RC) patients defined by magnetic resonance (MR): GEMCAD 0801 trial. J Clinc Oncol 30 (Suppl;abstract 3586)

    Google Scholar 

  • Fernández-Martos C, Pericay C, Aparicio J et al (2010) Phase II, randomized study of concomitant chemoradiation followed by surgery and adjuvant capecitabine plus oxaliplatin (capox) compared with induction capox followed by concomitant chemoradiation and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: grupo cancer de recto 3 study. J Clin Oncol 28(5):859–865

    Article  PubMed  Google Scholar 

  • Frasson M, Garcia-Granero E, Roda D, et al (2011) Preoperative chemoradiation may not always be needed for patients with T3 and T2N + rectal cancer. Cancer. doi: 10.1002/cncr.25866. (Epub ahead of print)

  • Frykholm GJ, Pahlman L, Glimerlius B (2001) Combined chemo- and radiotherapy vs. radiotherapy alone in the treatment of primary, nonresectable adenocarcinoma of the rectum. Int J Radiat Oncol Biol Phys 50(2):427–434

    Article  CAS  PubMed  Google Scholar 

  • Garcia-Aguilar J, Smith DD, Avila K et al (2011) Timing of Rectal Cancer Response to Chemoradiation Consortium. Optimal timing of surgery after chemoradiation for advanced rectal cancer: preliminary results of a multicenter, nonrandomized phase II prospective trial. Ann Surg 254(1):97–102

    Article  PubMed Central  PubMed  Google Scholar 

  • Garlipp B, Ptok H, Schmidt U, Stübs P, Scheidbach H, Meyer F, Gastinger I, Lippert H (2012) Factors influencing the quality of total mesorectal excision. Br J Surg 99(5):714–720

    Article  CAS  PubMed  Google Scholar 

  • Gerard JP, Conroy T, Bonnetain F et al (2006) Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-T4 rectal cancers: results of FFCD 9203. J Clin Oncol 24:4620–4625

    Article  PubMed  Google Scholar 

  • Gerard JP, Azria D, Gourgou-Bourgade S et al (2010) Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the Phase III trial ACCORD 12/0405-Prodige 2. J Clin Oncol 28:1638–1644

    Article  CAS  PubMed  Google Scholar 

  • Gerard JP, Azria D, Gourgou-Bourgade S et al (2012) Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 30(36):4558–4565

    Article  CAS  PubMed  Google Scholar 

  • Glynne-Jones R, Anyamene N, Moran B, Harrison M (2012) Neoadjuvant chemotherapy in MRI-staged high-risk rectal cancer in addition to or as an alternative to preoperative chemoradiation? Ann Oncol 23(10):2517–2526

    Google Scholar 

  • Gunderson LL, Sargent DJ, Tepper JE et al (2004) Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 22:1785–1796

    Article  PubMed  Google Scholar 

  • Herman MP, Kopetz S, Bhosale PR, Eng C, Skibber JM, Rodriguez-Bigas MA, Feig BW, Chang GJ, Delclos ME, Krishnan S, Crane CH, Das P (2009) Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course. Int J Radiat Oncol Biol Phys 74(3):818–823

    Article  PubMed Central  PubMed  Google Scholar 

  • Hermanek P, Heald RJ (2004) Pre-operative radiotherapy for rectal carcinoma? Has the case really been made for short course pre-operative radiotherapy if surgical standards for rectal carcinoma are optimal? Colorectal Dis. Review 6(1):10–4

    Google Scholar 

  • Ishii Y, Hasegawa H, Endo T et al (2010) Medium-termresults of neoadjuvant systemic chemotherapy using irinotecan, 5-fluorouracil, and leucovorin in patients with locally advanced rectal cancer. Eur J Surg Oncol 36(11):1061–1065

    Article  CAS  PubMed  Google Scholar 

  • Kuebler JP, Wieand HS, O’Connell MJ et al (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25(16):2198–2204

    Article  CAS  PubMed  Google Scholar 

  • Kusters M, Marijnen CA, van de Velde CJ et al (2010) Patterns of local recurrence in rectal cancer; a study of the Dutch TME trial. Eur J Surg Oncol 36(5):470–476

    Article  CAS  PubMed  Google Scholar 

  • Lange MM, den Dulk M, Bossema ER et al (2007) Risk factors for faecal incontinence after rectal cancer treatment. Cooperative clinical investigators of the Dutch total mesorectal excision trial. Br J Surg 94(10):1278–1284

    Article  CAS  PubMed  Google Scholar 

  • Marijnen CA, van de Velde CJ, Putter H et al (2005) Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial. J Clin Oncol 23(9):1847–1858

    Article  PubMed  Google Scholar 

  • Mathis KL, Larson DW, Dozois EJ et al (2012) Outcomes following surgery without radiotherapy for rectal cancer. Br J Surg 99(1):137–143

    Article  CAS  PubMed  Google Scholar 

  • MERCURY Study Group (2007) Extramural depth of tumour invasion at thin section MR in patients with rectal cancer. Results of the MERCURY Study. Radiology 243:132–139

    Article  Google Scholar 

  • Merkel S, Mansmann U, Siassi M, Papadopoulus T, Hohenberger W, Heranek P (2001) The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis 16:298–304

    Article  CAS  PubMed  Google Scholar 

  • Morris E, Quirke P, Thomas JD et al (2008) Unacceptable variation in abdominoperineal excision rates for rectal cancer: time to intervene? Gut 57(12):1690–1697

    Article  CAS  PubMed  Google Scholar 

  • Ngan S, Fisher R, Goldstein D et al (2010) TROG, AGITG, CSSANZ, and RACS.A randomized trial comparing local recurrence (LR) rates between short-course (SC) and long-course (LC) preoperative radiotherapy (RT) for clinical T3 rectal cancer: an intergroup trial (TROG, AGITG, CSSANZ, RACS). J Clin Oncol 28(15 Suppl) abstract 3509

    Google Scholar 

  • O’Connell MJ, Martenson JA, Wieand HS et al (1994) Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331(8):502–507

    Article  PubMed  Google Scholar 

  • Pachler J, Wille-Jørgensen P (2012) Quality of life after rectal resection for cancer, with or without permanent colostomy. Cochrane Database Syst Rev 12:CD004323 (Review)

    Google Scholar 

  • Peeters KC, van de Velde CJ, Leer JW et al (2005) Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients–a Dutch colorectal cancer group study. J Clin Oncol 23(25):6199–6206

    Article  CAS  PubMed  Google Scholar 

  • Peeters KC, Marijnen CA, Nagtegaal ID, et al (2007) for the Dutch Colorectal Cancer Group. The TME Trial after a Median Follow-up of 6 Years: Increased local control but no survival benefit in irradiated patients with resectable rectal Carcinoma. Ann Surg 246(5):693–701

    Google Scholar 

  • Perez RO, Seid VE, Bresciani EH, Bresciani C, Proscurshim I, Pereira DD, Kruglensky D, Rawet V, Habr-Gama A, Kiss D (2008) Distribution of lymph nodes in the mesorectum: how deep is TME necessary? Tech Coloproctol 12(1):39–43

    Article  CAS  PubMed  Google Scholar 

  • Pollack J, Holm T, Cedermark B et al (2006) Long-term effect of preoperative radiation therapy on anorectal function. Dis Colon Rectum 49(3):345–352

    Article  PubMed  Google Scholar 

  • Pollheimer MJ, Kornprat P, Pollheimer VS, Lindtner RA, Schlemmer A, Rehak P, Langner C (2010) Clinical significance of pT sub-classification in surgical pathology of colorectal cancer. Int J Colorectal Dis 25(2):187–196

    Article  PubMed  Google Scholar 

  • Quirke P, Steele R, Monson J et al (2009) MRC CR07/NCIC-CTG CO16 Trial Investigators; NCRI colorectal cancer study group. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 373(9666):821–828

    Article  PubMed Central  PubMed  Google Scholar 

  • Rödel C, Liersch T, Hermann R et al (2007) Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol 25:668–674

    Google Scholar 

  • Rödel C, Liersch T, Becker H et al (2012) Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: initial results of the German CAO/ARO/AIO-04 randomised phase 3 trial. Lancet Oncol 13(7):679–687

    Article  PubMed  Google Scholar 

  • Roh MS, Colangelo LH, O’Connell MJ et al (2009) Preoperative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum: NSABP-R03. J Clin Oncol 27:5124–5130

    Article  PubMed Central  PubMed  Google Scholar 

  • Roh MS, Yothers GA, O’Connell MH et al (2011) The impact of capecitabine and oxaliplatin in the preoperative mutli modality treatment in patients with carinoma of the rectum: NSABP R-04J. Clin Oncol 29(suppl;abstr 3503)

    Google Scholar 

  • Sauer R, Becker H, Hohenberger W et al (2004) German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351:1731–1740

    Article  CAS  PubMed  Google Scholar 

  • Schmoll H-J, Haustermans K, Price TJ, et al (2013) Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: first results of the PETACC-6 randomized trial (abstract). J Clin Oncol 31(suppl; abstr 3531)

    Google Scholar 

  • Schrag D, Weiser MR, Goodman KA et al (2014) Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol 32(6):513–518

    Article  CAS  PubMed  Google Scholar 

  • Sebag-Montefiore D, Stephens RJ, Steele R et al (2009) Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 373(9666):811–820

    Article  PubMed Central  PubMed  Google Scholar 

  • Smith N, Brown G (2008) Preoperative staging of rectal cancer. Acta Oncol 47(1):20–31

    Article  PubMed  Google Scholar 

  • Smith NJ, Barbachano Y, Norman AR et al (2008) Prognostic significance of magnetic resonance imaging-detected extramural vascular invasion in rectal cancer. Br J Surg 95(2):229–236

    Article  CAS  PubMed  Google Scholar 

  • Sternberg A, Amar M, Alfici R, Groisman G (2002) Conclusions from a study of venous invasion in stage IV colorectal adenocarcinoma. J Clin Pathol 55(1):17–21

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  • Syk E, Torkzad MR, Blomqvist L, Nilsson PJ, Glimelius B (2008) Local recurrence in rectal cancer: anatomic localization and effect on radiation target. Int J Radiat Oncol Biol Phys 72(3):658–664

    Article  PubMed  Google Scholar 

  • Taylor FG, Quirke P, Heald RJ,et al for the MERCURY study group (2011) Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, european study that recruited consecutive patients with rectal cancer. Ann Surg 253(4):711–719

    Google Scholar 

  • Tepper JE, O’Connell, Niedzwiecki D, Hollis DR, Benson AB 3rd, Cummings B, et al (2002) Adjuvant therapy in rectal cancer: analysis of stage, sex and local control—final report of intergroup 0114. J Clin Oncol 20:1744–1750

    Google Scholar 

  • van Gijn W, Marijnen CA, Nagtegaal ID et al (2011) Dutch Colorectal Cancer Group. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 12(6):575–582

    Article  PubMed  Google Scholar 

  • Willett CG, Badizadegan K, Ancukiewicz M et al (1999) Prognostic factors in stage T3N0 Rectal Cancer: Do all patients require postoperative pelvic irradiation and chemotherapy? Dis Colon Rectum 42:167–173

    Article  CAS  PubMed  Google Scholar 

  • Wolmark N, Wieand HS, Hyams DM, Colangelo L, Dimitrov NV, Romond EH et al (2000) Randomised trial of postoperative adjuvant chemotherapy with or without radiotherapy for carcinoma of the rectum: National Surgical Adjuvant Breast and Bowel Project Protocol R-02. J Natl Cancer Inst 92:388–396

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Radiotherapy Department, Mount Vernon Centre for Cancer Treatment, Rickmansworth Road, Northwood, London, Middlesex, HA6 2RN, UK

    Rob Glynne-Jones

Authors
  1. Rob Glynne-Jones
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rob Glynne-Jones .

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, Tumor- und Brustzentrum ZeTuP, St. Gallen, Switzerland

    Florian Otto

  2. Caritasklinik St. Theresia, Saarbrücken, Germany

    Manfred P. Lutz

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Glynne-Jones, R. (2014). Do T3 Rectal Cancers Always Need Radiochemotherapy?. In: Otto, F., Lutz, M. (eds) Early Gastrointestinal Cancers II: Rectal Cancer. Recent Results in Cancer Research, vol 203. Springer, Cham. https://doi.org/10.1007/978-3-319-08060-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-08060-4_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-08059-8

  • Online ISBN: 978-3-319-08060-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation